Connection

GABRIEL LOPEZ to Neoplasms

This is a "connection" page, showing publications GABRIEL LOPEZ has written about Neoplasms.
Connection Strength

0.473
  1. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.
    View in: PubMed
    Score: 0.072
  2. Nanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13.
    View in: PubMed
    Score: 0.071
  3. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.
    View in: PubMed
    Score: 0.055
  4. Liposomal antisense oligonucleotides for cancer therapy. Methods Enzymol. 2004; 387:241-53.
    View in: PubMed
    Score: 0.036
  5. GRB2: a pivotal protein in signal transduction. Semin Oncol. 2001 Oct; 28(5 Suppl 16):142-7.
    View in: PubMed
    Score: 0.031
  6. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid. Blood. 1996 May 01; 87(9):3650-4.
    View in: PubMed
    Score: 0.021
  7. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell. 2016 Feb 18; 61(4):520-534.
    View in: PubMed
    Score: 0.021
  8. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun. 2014 Dec 05; 5:5671.
    View in: PubMed
    Score: 0.019
  9. Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther. 2014 Dec; 13(12):2876-85.
    View in: PubMed
    Score: 0.019
  10. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell. 2013 Aug 12; 24(2):229-41.
    View in: PubMed
    Score: 0.018
  11. Tumour angiogenesis regulation by the miR-200 family. Nat Commun. 2013; 4:2427.
    View in: PubMed
    Score: 0.017
  12. MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer. 2011 Jun; 30(6):368-70.
    View in: PubMed
    Score: 0.015
  13. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer. 2011 Jan; 11(1):59-67.
    View in: PubMed
    Score: 0.015
  14. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010 Apr; 6(3):322-9.
    View in: PubMed
    Score: 0.014
  15. Strategies for in vivo siRNA delivery in cancer. Mini Rev Med Chem. 2008 Mar; 8(3):248-55.
    View in: PubMed
    Score: 0.012
  16. Effector mechanisms of human monocyte-mediated tumor cytotoxicity in vitro: biochemical, functional, and serological characterization of cytotoxins produced by peripheral blood monocytes isolated by counterflow elutriation. Cancer Res. 1986 Jun; 46(6):2871-5.
    View in: PubMed
    Score: 0.011
  17. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study. J Infect Dis. 1985 Apr; 151(4):704-10.
    View in: PubMed
    Score: 0.010
  18. Monocyte subpopulations in angiogenesis. Cancer Res. 2014 Mar 01; 74(5):1287-93.
    View in: PubMed
    Score: 0.005
  19. Phase I clinical and pharmacological study of liposome-entrapped cis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II). Cancer Res. 1990 Jul 15; 50(14):4254-9.
    View in: PubMed
    Score: 0.004
  20. Potentiation of direct antitumor cytotoxicity and production of tumor cytolytic factors in human blood monocytes by human recombinant interferon-gamma and muramyl dipeptide derivatives. Cancer Immunol Immunother. 1986; 21(2):93-9.
    View in: PubMed
    Score: 0.003
  21. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77.
    View in: PubMed
    Score: 0.003
  22. Mononuclear phagocyte system cytotoxins: a review. Nat Immun Cell Growth Regul. 1985; 4(2):78-89.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.